Breast Cancer Therapeutics in Major Developed Markets to 2021 - Problems With the Reimbursement of Premium-Priced Therapeutics Will Limit Their Uptake - Research and Markets

Apr 28, 2016, 07:10 ET from Research and Markets

DUBLIN, April 28, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence" report to their offering. 
     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO )

Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options. 

Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response. 

Scope 

The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent. 
- What are the competitive advantages of the existing novel drugs? 

With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates. 
- Which classes of novel drugs are most prominent within the pipeline? 
- Is there strong potential for the pipeline to address unmet needs within the breast cancer market? 

Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%. 
- How do failure rates vary by product stage of development, molecule type, and mechanism of action? 
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development? 

Over the 2014-2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion
- Which markets make the most significant contribution to the current market size? 
- What are the epidemiology trends in these markets? 
- Will new market entrants lead to substantial changes in annual therapy costs? 
- How will different treatment usage patterns impact growth in the eight major markets? 

Rising breast cancer incidence and new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations. 
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs? 
- Which patent expirations will have the most significant impact on the market? 

Key Topics Covered: 

1 Tables &  Figures 

2 Introduction 
2.1 Disease Introduction 
2.2 Symptoms 
2.3 Etiology 
2.4 Pathophysiology 
2.5 Epidemiology 
2.6 Diagnosis and Classification 
2.7 Prognosis and Disease Staging 
2.8 Treatment Options 
2.9 Treatment Guidelines 

3 Marketed Products 
3.1 Overview 
3.1.1 Herceptin (trastuzumab) - Genentech 
3.1.2 Perjeta (pertuzumab) - Genentech 
3.1.3 Afinitor (everolimus) - Novartis 
3.1.4 Tykerb/ Tyverb (lapatinib ditosylate monohydrate) - Novartis 
3.1.5 Ibrance (palbociclib) - Pfizer 
3.1.6 Ixempra (ixabepilone) - Bristol-Myers Squibb 
3.1.7 Halaven (eribulin mesylate) - Eisai 
3.1.8 Avastin (bevacizumab) - Genentech 
3.1.9 Kadcyla (ado-trastuzumab emtansine) - Genentech 
3.1.10 Marketed Products Heatmap 
3.1.11 Measuring the Effectiveness of Treatment 
3.2 Conclusion 

4 Pipeline Products 
4.1 Pipeline Products 
4.2 Clinical Trials 
4.3 Competitive Clinical Trials Metrics Analysis 

5 Promising Drug Candidates in Pipeline 
5.1 Abemaciclib - Eli Lily 
5.2 Buparlisib - Novartis 
5.3 NeuVax (nelipepimut-S) - Galena Biopharma 
5.4 Niraparib - Tesaro 
5.5 Lynparza (Olaparib) - AstraZeneca 
5.6 Veliparib - AbbVie 
5.7 Neratinib - Puma Biotechnology 
5.8 Ribociclib - Novartis 
5.9 Talazoparib - BioMarin 
5.10 Alpelisib - Novartis 
5.11 Atezolizumab - Roche 
5.12 Entinostat - Syndax 
5.13 Margetuximab - MacroGenics 
5.14 Taselisib - Genentech 
5.15 OBI-822/821 - OBI Pharma 
5.16 Heat Map for Pipeline Products 

6 Market Forecast to 2021 

7 Drivers and Barriers for the Disease Market 
7.1 Drivers 
7.1.1 Increased Uptake of Targeted and Combination Therapies for Breast Cancer 
7.1.2 Growth and Aging of Western Populations 
7.1.3 Launch of Premium-Priced Products with Greater Efficacy than Existing Therapies 
7.2 Barriers 
7.2.1 Patent Expiries 
7.2.2 High Level of Competition 
7.2.3 Problems with the Reimbursement of Premium-Priced Therapeutics will Limit their Uptake 

8 Deals and Strategic Consolidations 
8.1 Licensing Deals 
8.1.1 Sprint Bioscience Enters Licensing Agreement with Bayer HealthCare 
8.1.2 Takeda Enters Licensing Agreement with ImmunoGen 
8.1.3 Oncothyreon Enters Licensing Agreement with Array BioPharma for ONT-380 
8.1.4 Halozyme Therapeutics Enters Licensing Agreement with Janssen Biotech 
8.1.5 CTI BioPharma Enters Licensing Agreement with Servier for Pixuvri 
8.2 Co-development Deals 
8.2.1 MacroGenics Enters Agreement with Merck 
8.2.2 Color Genomics Partners with University of California Health 
8.2.3 Lycera Enters Co-development Agreement with Celgene 
8.2.4 Roche Holding Enters Agreement with Oryzon to Develop Epigenetics-Based Medicines 
8.2.5 Tracon Enters Co-development Agreement with Santen Pharma 

9 Appendix 

Companies Mentioned 

- AbbVie 
- Array BioPharma 
- AstraZeneca 
- Bayer HealthCare 
- BioMarin 
- Bristol-Myers Squibb 
- CTI BioPharma 
- Celgene 
- Color Genomics 
- Eisai 
- Eli Lily 
- Galena Biopharma 
- Genentech 
- Halozyme Therapeutics 
- ImmunoGen 
- Janssen Biotech 
- Lycera 
- MacroGenics 
- Merck 
- Novartis 
- OBI Pharma 
- Oncothyreon 
- Oryzon 
- Pfizer 
- Puma Biotechnology 
- Roche 
- Santen Pharma 
- Servier 
- Sprint Bioscience 
- Syndax 
- Takeda 
- Tesaro 
- Tracon 

For more information visit http://www.researchandmarkets.com/research/5h7p86/breast_cancer


Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets